Assessing biosimilars in the real world setting

Practical guidance on the assessment of biosimilar monoclonal antibodies: A pharmacist's perspective

Effective communication about biosimilars

The role of the pharmacist in supporting multi-disciplinary education

Comment: Immunogenicity of biosimilars

Comment: Critical quality attributes of biosimilars

Comment: Use of biosimilar monoclonal antibodies in the clinic

Comment: Supporting a sustainable biosimilar solution

Realising the potential of biosimilars

Simplifying molecular subtypes of metastatic gastric cancer

Quality of life results from pembrolizumab vs chemotherapy in gastric or gastroesophageal junction cancer

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy